<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930317</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ-NXBYZ</org_study_id>
    <nct_id>NCT02930317</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A</brief_title>
  <official_title>An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of rFVIII in the Prevention and Treatment of Bleeding Episodes in Chinese With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy, Safety and Pharmacokinetics Study of a rFVIII in Chinese subjects with Hemophilia
      A.To assess efficacy and safety of rFVIII administered as treatment and as on-demand therapy
      in adult and adolescent (12-65 years) patients with severe or moderately severe Hemophilia A.
      To determine the pharmacokinetic (PK) parameters of rFVIII.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery rate = (change actual value of rFVIII activity before and after infusion )/(change expected value of rFVIII activity before and after infusion)*100%</measure>
    <time_frame>At 15 and 60 minutes after the first infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Hemostatic Efficacy Assessment 6 Hours Post Infusion</measure>
    <time_frame>6 hours post infusion</time_frame>
    <description>The Investigator Hemostatic Efficacy Assessment was based on a 4-point rating scale (Excellent = 1: definite pain relief or improvement in signs of bleeding, with no additional infusion, Good = 2: definite pain relief or improvement in signs of bleeding, Moderate = 3: probable or slight improvement, No Response = 4: no improvement at all between infusions).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieved the expected effect after the first infusion of the rFVIII</measure>
    <time_frame>At 15 minutes after the first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change actual value of rFVIII activity before and after infusion levels</measure>
    <time_frame>At 15 and 60 minutes after the first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVIII Maximum Plasma Concentration</measure>
    <time_frame>Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration</measure>
    <time_frame>Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours</measure>
    <time_frame>Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 28 days after last dose</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetic parameters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On-demand treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years. In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Factor VIII (50 IU/kg)</intervention_name>
    <arm_group_label>Pharmacokinetic parameters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Factor VIII (On-demand treatment)</intervention_name>
    <arm_group_label>On-demand treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hemophilia A

          -  Age of 12 Years to 65 Years，Diagnosis of severe （defined as &lt;1% FVIII:C documented in
             medical records） or moderately severe（defined as 1%-5% FVIII:C documented in medical
             records） hemophilia A .Subjects who（Age of 18 Years to 65 Years） have received or are
             currently receiving FVIII products (plasma-derived and/or recombinant FVIII) and have
             had &gt;150 exposure days (EDs) with a FVIII product；The Callan (Age of 12 Years to 17)
             have received FVIII products and have had&gt;50 EDs a FVIII product.

          -  Subjects without a past history of, or current no factor VIII inhibitor. For
             laboratory-based assessments, any Bethesda inhibitor titer Lower than the laboratory's
             normal range or ＜0.6 BU/mL (BU:Bethesda Units ).

          -  Liver and kidney function in accordance with the standard

          -  Subjects of childbearing potential should agree to use and utilize an adequate method
             of contraception throughout treatment and for at least 28 days after study is stopped

          -  Evidence of a personally or legally acceptable representative (legally acceptable
             representative is only applicable to Callan subjects) signed and dated informed
             consent document indicating that the subject has been informed of all pertinent
             aspects of the study

          -  The part one of subjects subjects who are willing and able to comply with scheduled
             visits, treatment plan, laboratory tests, and other study procedures; Subjects must be
             in a non bleeding state before the administration of rFVIII on Day 1; Subjects should
             not have received an infusion of any FVIII products for at least 3 days (at least 72
             hours) before the administration of rFVIII on Day 1

        Exclusion Criteria:

          -  Current FVIII inhibitor or history of FVIII inhibitor (＞0.6 BU/mL )

          -  Diagnosed with any bleeding disorder in addition to hemophilia

          -  Documented Human Immunodeficiency Virus (HIV)

          -  Subjects anticipating elective surgery or other invasive procedure within 1 month
             following study entry

          -  Treatment with an immunomodulatory within 30 days or 5 half lives preceding Day 1,
             whichever is longer

          -  Subjects with known hypersensitivity to the active substance or to any of the
             excipients of rFVIII. Subjects with a known hypersensitivity to Chinese Human
             embryonic kidney cell proteins

          -  Subjects with severe anemia requiring blood transfusion

          -  Subjects with significant hepatic or renal impairment (alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST) &gt;5 x ULN, or total bilirubin &gt;2 x ULN or serum
             creatinine &gt;2 x ULN), prothrombin time &gt;1.5 x ULN, platelet count &lt;80,000 μL. History
             of sensitivity to heparin or heparin induced thrombocytopenia or others
             thrombocytopenia

          -  Patients with heart surgery history requires anticoagulation therapy; Subjects with
             severe heart disease, including myocardial infarction or heart failure Grade 3 or
             higher(NYHA Classification)

          -  Blood pressure unable to be controlled ideally(systolic pressure＞150 mmHg，diastolic
             pressure＞90 mmHg)

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Zhang, Doctor</last_name>
    <email>zlpumc@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui provincial hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zimin Sun, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuefeng Wang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linhua Yang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology)</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Zhang, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

